Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Independent associations between change in DXR-BMD and baseline serological biomarkers (multivariate linear regression analyses)

From: Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study

  One-year DXR-BMD change Two-year DXR-BMD change Five-year DXR-BMD change
  B
(95% CI)
P value B
(95% CI)
P value B
(95% CI)
P value
Anti-CCP (> 25 U/ml) -1.7
(-2.8 to -0.7)
0.002 -2.1
(-3.5 to -0.6)
0.006 -5.5
(-7.8 to -3.1)
< 0.001
ESR (> 20 mm/h) -2.5
(-3.6 to -1.4)
< 0.001 -3.2
(-4.7 to -1.7)
< 0.001 -5.2
(-7.6 to -2.8)
< 0.001
CRP (> 10 mg/l)    -1.8
(-3.4 to -0.3)
0.02   
DMARD treatment    -1.4
(-2.8 to -0.03)
0.05   
Age (years) -0.02
(-0.07 to 0.02)
0.3 -0.05
(-0.1 to 0.002)
0.06 -0.08
(-0.2 to 0.01)
0.09
Sex (female) 0.3
(-0.8 to 1.5)
0.6 0.1
(-0.3 to 2.8)
0.1 0.5
(-2.1 to 3.1)
0.5
Constant 0.5
(-1.9 to 3.1)
0.7 1.8
(-1.5 to 5.1)
0.3 1.8
(-3.6 to 7.2)
0.5
Adjusted R2 21.1%   29.3%   28.5%  
  1. Final models after multivariate linear regression analyses. Dependent variable: DXR-BMD change (%).
  2. Anti-CCP = antibodies to cyclic citrullinated peptide; CI = confidence interval; CRP = C-reactive protein; DMARD = disease-modifying antirheumatic drugs; DXR-BMD = hand bone mineral density estimated by digital X-ray radiogrammetry; ESR = erythrocyte sedimentation rate.